Market capitalization | $2.65b |
Enterprise Value | $2.58b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 129.56 |
EV/Sales (TTM) EV/Sales | 4.70 |
P/S ratio (TTM) P/S ratio | 4.84 |
P/B ratio (TTM) P/B ratio | 6.25 |
Revenue growth (TTM) Revenue growth | 24.67% |
Revenue (TTM) Revenue | $547.47m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
15 Analysts have issued a Inari Medical Inc forecast:
15 Analysts have issued a Inari Medical Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 547 547 |
25%
25%
|
|
Gross Profit | 468 468 |
22%
22%
|
|
EBITDA | -9.58 -9.58 |
31%
31%
|
EBIT (Operating Income) EBIT | -23 -23 |
3%
3%
|
Net Profit | -57 -57 |
255%
255%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It produces ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.
Head office | United States |
CEO | Andrew Hykes |
Employees | 1,300 |
Founded | 2011 |
Website | www.inarimedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.